Tests aritinercept in adults with generalized myasthenia gravis
Tests aritinercept, a new drug, in adults with generalized myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Key facts
- Where
- Altamonte Springs, Boca Raton, Chicago, Dearborn, Flint, Homestead, Houston, Miami, O'Fallon, and Pasadena, United StatesSee the 10 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07596901, who can take part
Where in United States
- Altamonte SpringsAltamonte Springs, United StatesTaking people
- Boca RatonBoca Raton, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- DearbornDearborn, United StatesTaking people
- FlintFlint, United StatesTaking people
- HomesteadHomestead, United StatesTaking people
- HoustonHouston, United StatesTaking people
- MiamiMiami, United StatesTaking people
- O'FallonO'Fallon, United StatesTaking people
- PasadenaPasadena, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aurinia Pharmaceuticals Inc.
- Trial code
- NCT07596901
- Record updated
- 3 August 2026
- Original description
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.Read full original descriptionShow less
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Inclusion: Adult patients (18-85 years old); Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG; Additional inclusion criteria are defined in the protocol.
Exclusion: Current or medical history of malignancy within the last 5 years; Pregnant, breastfeeding or intending to become pregnant during the Study; Additional exclusion criteria are defined in the protocol.